Guangzhou Jiuzhitang

Guangzhou Jiuzhitang Biological Technology is a specialized biotechnology subsidiary of the historic Chinese pharmaceutical group Jiuzhitang Co., Ltd., focused on the development of regenerative medicine and stem cell therapies. Established in 2018, the company operates a state-of-the-art R&D and manufacturing facility in Guangzhou's International Bio Island, adhering to international GMP standards. Its primary focus is the clinical application of Mesenchymal Stem Cells (MSCs) for high-unmet-need conditions, particularly ischemic stroke. The company is currently advancing its lead candidate, YB-209 (Stemsys), through clinical trials in China following a strategic partnership and investment in the US-based Stemedica Cell Technologies. By combining traditional pharmaceutical heritage with cutting-edge regenerative technology, Guangzhou Jiuzhitang aims to become a leader in the Chinese cell therapy market.